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Abstract 
Several community-based models for treating Hepatitis C Virus (HCV) infection have been 
implemented to improve treatment accessibility and health outcomes. However, there is a 
lack of knowledge regarding how well these models achieve the desired goals. We conducted 
a mixed-method systematic review of quantitative and qualitative evidence about clinical 
effectiveness, cost effectiveness and acceptability of community-based HCV treatment 
models. Seventeen databases were researched for published and unpublished studies. 
Methodological quality was assessed using The Joanna Briggs Institute Critical Appraisal 
tools. Quantitative findings were synthesised in narrative form and qualitative findings were 
synthesised using meta-synthesis. Forty-two quantitative and six qualitative studies were 
included. No relevant cost effectiveness studies were found. Five categories of community-
based models were identified: telehealth, integration of HCV and addiction services, 
integration of HCV and HIV services, integration of HCV and primary care, and 
implementation by a home care and health care management company. The range of reported 
outcomes included; end of treatment response: 48.7% to 96%, serious side effects: 3.3% to 
27.8%, sustained virological response: 22·3% to 95·5%, relapse: 2·2% to 16·7%, and 
treatment completion: 33·4% to 100%. Inconsistent measures of uptake and adherence were 
used; uptake ranged from 8·3% to 92%, and 68·4% to 100% of patients received ≥80% of 
prescribed doses. Patient reported experiences included trusted and supportive care providers, 
safe and trusted services, easily accessible care, and positive psychological and behavioural 
changes. The clinical effectiveness and acceptability reported from the included studies are 
similar to or better than reported outcomes from systematic reviews of studies in tertiary 
settings. Studies of the cost-effectiveness of community-based models for treating HCV are 
needed. 
Keywords: Hepatitis C, community-based, treatment, direct acting antivirals, primary health 
care 
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Introduction: 
Treatment of HCV improved dramatically when direct acting antivirals (DAAs) were 
introduced.
1, 2
 The previous interferon based regimens were poorly tolerated because of 
adverse side effects and low treatment success rates were achieved.
3
 The DAA based 
regimens have fewer side effects, shorter treatment duration and higher sustained virological 
response (SVR).
1, 2
 The DAAs provide an opportunity to develop and implement new models 
for treating HCV and to provide HCV treatment near targeted populations to increase the 
treatment uptake, compliance and completion rates.
2, 4, 5
 The administration of DAAs is less 
complicated, requiring minimal monitoring and the provision of  HCV treatment in 
community settings is emphasised as an alternative model for HCV treatment.
3, 6, 7
 Several 
community-based models for treating HCV have been implemented and evaluated in 
different regions to improve the treatment accessibility and outcomes. The community-based 
models for treating HCV should be clinically effective to improve quality of care and 
decrease burden of HCV infection.
3, 6, 7
 Also, the HCV treatment service needs be acceptable 
for patients in order to successfully engage and commence treatments. The cost effectiveness 
of these models is an important area where further research is urgently required, to help 
policy-makers invest wisely.
7, 8
 Currently, there is a lack of knowledge regarding clinical 
effectiveness, cost effectiveness and acceptability of providing HCV treatment in different 
community settings. 
 
To develop a better understanding of the outcomes of community-based models of care a 
range of outcomes and patients’ experience should be considered and context of the 
community-based settings needs to be taken into account in the analyses. The current 
systematic review is a mixed methods review aimed to develop an aggregated synthesis of 
quantitative, qualitative and economic evidence to have a better understanding of the clinical 
effectiveness, acceptability and cost-effectiveness of providing HCV treatment in community 
settings. The overarching question is: What is the clinical effectiveness, acceptability and 
cost-effectiveness of community-based models for treating chronic HCV? 
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Method: 
The protocol for this review is registered on the PROSPERO database (PROSPERO 2017 
CRD42017064250) and published.
9 
 
Inclusion criteria 
The review considered all quantitative and economic studies that evaluated community-based 
models for treating adults who were diagnosed with chronic HCV.  The review also included 
qualitative studies of adult patients’ experiences of community-based models for treating 
chronic HCV. The community services were defined as any medical services which were not 
provided in hospital or academic tertiary settings.  Telehealth services were included. 
Excluded studies were those that were based on mathematical modelling or reported HCV 
management in prisons, or were based solely in private gastroenterologist or hepatologist 
clinics. We have excluded studies that reported HCV treatment in gastroenterologist or 
hepatologist clinics outside hospital (i.e. specialists who were practicing in their private 
clinic) as the focus of this study was on community and primary care based models. 
 
Search strategy 
Studies published after 2000 (when pegylated interferon was introduced)
10
 were considered 
for inclusion.  No language limits were used. The initial search of databases was carried out 
in September 2016 and updated on 18 September 2017.  
 
Published studies were sought through: CINAHL, Cochrane Library, Embase, MEDLINE 
(PubMed), ProQuest, Primary Health Care Research and Information Service, PsycINFO, 
Scopus, Web of Science. Unpublished studies were sought through Canada Theses Portal, 
Clinicaltrials.gov, Google Grey, Mednar, Open Gray, ProQuest Dissertations and Theses 
Global, Trove, Websites of relevant organizations included WHO, World Gastroenterology 
Organization, American Association for the Study of Liver Diseases and European 
Association for the Study of the Liver. The search strategy in PubMed is provided in 
appendix A. 
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Assessment of methodological quality 
Methodological validity of all relevant studies prior to inclusion in the review was assessed 
using The Joanna Briggs Institute (JBI) Critical Appraisal tools by first author (DP) and was 
independently reviewed by a second author (LH). Disagreements between the two reviewers 
were resolved through discussion and referral to the other authors in a group discussion until 
consensus was reached. 
 
Data extraction 
Quantitative outcomes were extracted based on ‘intention to treat’ when possible.  Authors of 
some included papers were contacted to obtain information that was not reported in the 
methods and results. Extracted data was independently reviewed by two reviewers (DP and 
LH), and differences were reviewed and discussed until consensus was reached. 
 
Data synthesis 
Quantitative findings were synthesised in narrative form including categorising models based 
on their similarity of setting, description of each models and reporting measured outcomes to 
aid in data presentation. Qualitative research findings were synthesised to generate a set of 
statements using a meta-synthesis method.
11
 The findings and their supporting quotes were 
extracted and organised into tentative categories based on their similarity of meaning. 
Subsequently, the categories were combined and synthesised. 
 
Results 
Search results  
Among 8532 identified titles, 42 quantitative and 6 qualitative research studies were included 
for data extraction. No relevant research articles reporting cost effectiveness of implementing 
a community-based model were found. Two studies were excluded after reading the full text 
as they re-reported findings of already included studies (i.e. duplication). 
12, 13
 (figure 1)  
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Methodological quality appraisal 
Three quantitative studies were excluded because their methodological quality was assessed 
as poor.
14-16
 Other studies were included for data extraction. 
 
Quantitative studies: 
Among 38 cross-sectional studies, inclusion criteria were not clearly defined in only one 
study.
17
 One study failed to describe the study participants and setting in detail,
18
 one study 
did not clearly mention how the exposure (receiving care at the community settings) was 
measured.
19
 The majority of studies failed to address confounders such as patients’ 
socioeconomic characteristics, HIV or HBV co-infections, history of HCV treatment and 
types of healthcare providers.
17-38
 The other criteria (standard criteria for measuring the 
condition, valid and reliable way for measuring the outcomes and appropriate statistical 
analysis) were met by all studies. Sixteen studies fulfilled all the eight criteria.
39-54 
 
There were three cohort studies - in one study there was a subgroup analysis with significant 
differences in some baseline characteristics between the two groups.
55
 In one study it was not 
clear how the exposure (receiving treatment at community settings) was measured.
56
 
Strategies to address incomplete follow-up were not applied in two studies,
55, 56
 and in one 
retrospective cohort study, it was not applicable.
57
 The other criteria (measuring exposure 
similarly to assign people to both exposed and unexposed groups, identifying and dealing 
with confounders, participants being free of outcomes at the start of the studies, measuring 
outcomes in a valid and reliable way, sufficient follow up time, and appropriate statistical 
analysis) were met by all studies. 
 
In the only randomised controlled trial (RCT), there were some differences in baseline 
characteristics between the two groups. Based on the characteristics of the intervention it was 
not possible for participants and care providers to be blinded. It was not clear if the outcomes 
assessor was blinded during treatment assignment and analysis. Deviations from the standard 
RCT design were not accounted in statistical analysis of the trial.
58 
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Qualitative studies: 
Among the six qualitative studies none reported the researchers’ cultural or theoretical 
positions.
59-64
 In one study the research methodology (qualitative approach for evaluation) 
and data collection method (telephone structured interview) were incongrous.
61
 Three studies 
also did not address the influence of the researcher on the research and vice-versa,
60, 63, 64
 and 
this issue was also unclear in one another study.
61
 The other criteria were met by all studies. 
 
Characteristics of included studies 
Data in published articles was collected between November 1998 and February 2017. 
Fourteen studies were from USA, 13 from Australia, 10 from Canada, six from the UK, two 
from Switzerland, and three studies were from the Netherlands, France and Pakistan.  
 
Various exclusion and inclusion criteria for treatment were applied in different studies. Six 
studies excluded treatment-experienced patients.
27, 39, 43, 46, 55, 57
 Six studies mentioned HIV 
co-infected patients were excluded
45, 46, 49, 50, 55, 57
 and four studies also excluded hepatitis B 
virus co-infected patients.
46, 50, 55, 57
 In eight studies active drug users were excluded.
20, 22, 23, 26, 
27, 44, 46, 57, 58
 Fourteen studies excluded patients with severe or uncontrolled mental health 
problems.
12, 18, 20, 22, 23, 27, 36, 41, 44-46, 48, 50, 57 
 
Prescribed medicines in the majority of studies were Pegylated-interferon (Peg-IFN) plus 
ribavirin (RBV). In three studies patients received RBV plus interferon or Peg-IFN
12, 24, 45
 and 
in three others interferon and RBV were prescribed for all patients.
18, 35, 37
 In five studies 
patients received interferon free or Peg-IFN plus RBV with or without DAAs
19, 21, 29, 34, 50
 and 
in four studies all patients were treated with interferon free treatment.
29, 47, 52, 53
 
Characteristics of included quantitative and qualitative studies are presented in table 1 and 2. 
 
Describing the models of care: 
A variety of community-based models for treating HCV were implemented in various 
settings. The models were organised into five categories based on the similarity of the 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
models' settings including: 1) Telehealth models
32, 55-57
 based on videoconferencing or 
teleconferencing among patients, community healthcare providers and a hospital based team. 
One of these models was a hepatology nurse-led telehealth.
32
 2) Integration of HCV and 
addiction services where HCV services were added to existing addiction services to make 
services more accessible for the patients and create more opportunities for engagement with 
the service’s clients.17-19, 22, 23, 27, 28, 30, 31, 33, 36-39, 41, 43, 45, 46, 48-50, 52, 54, 58-60, 62-64 3) Integration 
of HCV and HIV services where HCV services were added to existing HIV programs in a 
primary care clinic and a multidisciplinary team including an on-site hepatologist provide 
HCV care.
35
 4) Integration of HCV and primary care models where HCV services was 
provided in settings where patients received routine primary care,
12, 21, 24, 25, 29, 34, 40, 42, 47, 51, 53, 
61
 and 5) home care and health care management company models where HCV treatment was 
provided by a home care nurse in collaboration with a hospital liver clinic or a care 
management nurse supervised by a multidisciplinary committee in a care management 
company.
20, 26 
 
Most of the models were physician-led, but in some of the models, nurse practitioners or 
nurses were programme coordinators.
17, 19, 27, 32, 46
 They also initiated treatment and 
managed the patients in consultant with hepatologists or gastroenterologists in some 
models.
26, 28, 38, 46, 47, 55, 56
  
 
Quantitative Synthesis: 
Clinical Outcomes of the Models 
The included studies measured a wide range of outcomes. We examined outcomes of clinical 
effectiveness including: rapid virological response (RVR) at week 4 of treatment, early 
virological response (EVR) at week 12 of treatment, end of treatment response (ETR), SVR, 
incidence of serious side effects requiring termination of treatment and relapse rate; and 
acceptability including: uptake, adherence to treatment, and treatment completion (Table 3). 
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Clinical effectiveness: 
Rapid virological response and early virological response: 
In the integrated  HCV and addiction services models, in two studies 68%
50
 and 62%
43
 of 
patients achieved RVR and in one study EVR of 86% was reported.
43
 In one study EVR in 
the community setting was higher (83·3%) than in the tertiary centre (75%).
58
 In the 
integrated HCV and primary care models in the Baker et al study
40
 RVR and EVR were 
65·9% and 75·6, respectively, and in another study EVR of 90% in patients with genotype 
one was reported.
25 
 
End of treatment response: 
In the integrated HCV and addiction services models, ETR ranged from 48·7% in interferon 
plus RBV based regimen
18
 to 89% in interferon free therapy.
52
 In integrated HCV and 
primary care models ETR was 76·7% in a study on interferon based treatment 
25
 and 96% in 
a study using a interferon free regimen.
29
 In a home HCV care model ETR was 11·3%.
26 
 
Incidence of serious side effects requiring termination of treatment: 
In a nurse-led telehealth model, 10% of patients ceased treatment because of adverse events
32
 
and in a study comparing two approaches this figure in a telehealth model was significantly 
lower than a tertiary centre (4·2% vs. 8·9%, P = 0·02).
55
 In the integrated HCV and addiction 
services this figure ranged between 10·5%
18
 and 27·8%.
22
 In the HIV/HCV integrated model 
incidence of serious side effects requiring termination of treatment was reported in 23·1% of 
patients.
35
 In the integrated HCV and primary care models in the Ho et al study
25
 6·7% of 
patients experienced intolerable adverse events, and in the Kattakuzhy et al study
47
 where 
patients were treated with DAAs, treatment was stopped in 3·3% of patients because of 
adverse events. 
 
Sustained virological response: 
In telehealth models, SVR ranged from 55%
57
 to 72%
32
 and there were no significant 
differences between telehealth and the tertiary centre. In the integration of HCV and 
addiction services SVR ranged from 22·3% in Peg-IFN plus RBV based treatment
22
 to 80·3% 
in interferon free therapy.
52
 In six studies SVR rate was less than 50%
18, 22, 31, 36-38
 - in two of 
these studies patients received interferon plus RBV
18, 37
. In the Bruce et al study
58
 SVR in 
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community setting was 50% and in a tertiary centre was 25%. In the models integrating HCV 
and primary care, SVR ranged from 40% in Peg-IFN plus RBV treatment
51
 to 95·5% in a 
study where most of the patients received interferon free based regimen.
34
 In the home care 
and health care management companies’ models, 45%26 and 27·5%20 of patients achieved 
SVR, respectively. 
 
Relapse rate: 
In the nurse-led telehealth model the relapse rate was reported in a study as 4%.
32
 In the  
integration of HCV and addiction services in two studies, relapse was 14%
17
 and 8·6%.
54
 In 
Lewis et al study
28
 16·7% relapse rate was reported in patients who received treatment from 
nurse. In the integrated HCV and primary care models the relapse rate was reported  as 
5·8%,
47
 3%
21
 and 2·2%
34
 in studies where patients received DAAs based treatment.  
 
Acceptability: 
Treatment uptake:  
Treatment uptake was measured in different ways in different models. In addition, different 
inclusion and exclusion criteria applied in different studies and there was a wide range of 
uptake rates. In integrated HCV and addiction services models uptake rate ranged from 
8·3%
48
 to 69·7%.
27
 In one study providing HCV treatment in an addiction clinic improved 
the uptake rate significantly in comparison with a traditional hospital-based approach (2% vs. 
38%, P< 0·001).
31
 In the HCV/HIV integrated model only 10·5% of HCV patients initiated 
treatment.
35
 In the models integrating HCV and primary care, uptake ranged from 19%
51
 to 
77%.
24
 In the home HCV care model 92% of eligible patients initiated treatment.
26
  
 
Adherence to treatment:  
Patients’ adherence to treatment was measured in different ways in different models. In  
integrated HCV and addiction services, in three studies 68·4%,
18
 83%
28
 and 86%
43
 of patients 
received at least 80% of scheduled doses and 80% of scheduled treatment period. In one 
study it was reported that all patients took at least 80% of prescribed Peg-IFN and RBV
33
 and 
in another study 87·5% did not have any missed Peg-IFN.
42
 In Litwin et al study
50
 74% and 
64% of patients took at least 90% of the prescribed RBV and telaprevire/ bocoprevir, 
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respectively. In Morris et al study
52
 where patients received interferon free treatment 97% of 
patients took at least 90% of expected doses.  
 
In integrated HCV and primary care model in the Ho et al study,
25
 77% of patients attended at 
least 80% of recommended visits and 80% took at least 80% of prescribed doses. In studies 
on interferon free based treatment in one study 41% of patients missed at least one dose
29
 and 
in another study 62·2% of expected visits were attended by patients and 86·6% of expected 
prescriptions were picked up.
47 
 
Treatment completion:  
The completion rate was 70% in nurse-led telehealth.
32
 In one study treatment completion in 
a telehealth model was significantly higher than a tertiary based model (78% vs. 53%, P = 
0·03).
57
 In models integrating HCV and addiction services completion rates ranged between 
33·4%
22
 in Peg-IFN based treatment to 96·1% in an interferon free regimen.
52
 Except in two 
studies which reported the completion rate as 33·4%
22
 and 55%,
48
 in other studies more than 
60% of patients completed the treatment.
17, 18, 23, 27, 33, 37, 38, 41, 46
 In the HCV/HIV integrated 
model this figure was 47·8%.
35
 In the integrated HCV and primary care models, completion 
rate ranged from 60%
51
 to 100%.
34
 In the home HCV care model 92·5%
26
 and in the health 
care management company model 52·6% of patients completed the treatment.
20 
 
Qualitative Synthesis 
Thirty three findings were extracted and rated based on a JBI level of credibility.
65
 Eighty 
five percent of findings were rated as “unequivocal” (U) and the rest were “equivocal” (E). 
Based on the similarity in meaning, findings were collated into five categories including 
trusted and supportive care providers, safe and trusted settings, easy to access care, 
psychological changes, and behavioural changes (Table 4). 
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Category 1: Trusted and supportive care providers 
The relationship between community health care providers and patients was a key factor for 
engaging patients with the services. Being listened to, especially during the initial 
appointment,
63
 access to emotional support and high level of trust in care providers,
61
 
familiarity with care providers,
60
 and being recognised beyond their drug use
63
 were 
mentioned as a catalyst to initiate the treatment. The quality of the therapeutic interaction was 
important for patients to improve adherence to treatment.
63
 Providing convenience, safe, 
personal
61
 and respectful care
64
 welcoming and non-judgmental staff,
64
 being guided and 
supported rather than pushed into treatment,
64
 and a deep relationship with care providers
60
 
were characteristics of HCV treatment in the community settings which helped patients feel 
comfortable. On the other hand some studies reported the negative experience of patients in 
relationships with OST prescribers in collocated HCV and addiction services can negatively 
affect patients' perceptions of HCV care providers.
60, 64 
 
Category 2: Safe and trusted setting: 
The community setting was reported by patients as being a safe and trusted setting compared 
with hospitals.
64
 Familiarity and feeling safe in the community settings
60, 62
 and seeing other 
patients in a similar situation
60
 increased patients’ willingness to initiate their treatment and 
helped patients to feel comfortable. On the other hand unintended disclosure of HCV because 
of the design of the OST was seen as a barrier.
64 
 
Category 3: Easy to access care 
Collocation of HCV treatment and drug and alcohol services was mentioned as easy to 
access care
62, 64
 and facilitated initiating and continuing treatment.
64
 The availability of 
all needed services under one roof
62, 64
 and reduced travel cost were highlighted by 
patients.
64
  
 
Category 4: Psychological changes as a result of undertaking HCV treatment 
Taking more care about their life, enabling better self-control, developing  a sense of hope, 
and recovery from internalised stigma were mentioned by patients as resulting from 
undertaking HCV treatment in a community setting.
59
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Category 5: Behavioural changes as a result of undertaking HCV treatment: 
The desire to disclose HCV status, reduction in drug and alcohol use, looking for stable 
housing, transitioning into a healthier lifestyle, increased sense of responsibility in 
their lives, and a desire to help others were changes that patients experienced by taking 
HCV treatment in community-based models.
59
  
 
Synthesised finding: Community based models of care for HCV treatment allow easy to 
access care provided in a trusted, safe and supportive environment which can engage 
patients to treatment and improve their quality of life. 
 
Discussion 
In this review we systematically searched for all published and unpublished papers which 
reported evaluation results of models for treating HCV in any community setting. A majority 
of studies used a descriptive cross-sectional design (n= 38) to describe the outcomes of 
community-based models which showed comparable or better health outcomes for 
community based in comparison with published tertiary based studies. All three cohort 
studies compared the outcomes of telehealth with tertiary based treatment and showed the 
telehealth model is as effective as tertiary based models.
55-57
 One randomised controlled trial 
compared the outcomes of community-based models in a methadone maintenance program 
with a university based liver speciality clinic where outcomes of community based models 
were better than the tertiary service.
58
 The qualitative studies showed the acceptability of 
providing HCV treatment in the community settings. Overall, the results of this review 
suggest that community-based models are acceptable and clinically effective and, where 
comparisons have been made with tertiary-based models of care, comparable outcomes were 
found. 
 
Various community-based models of care were developed and implemented based on 
different settings and target groups. Because HCV is prevalent in people who use drugs, a 
majority of models were designed and implemented in drug and alcohol services to make 
services more accessible for the patients and allow for more opportunities to engage with the 
drug and alcohol services’ clients. 
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Strengths and limitations of the study 
This systematic review is the first mixed method systematic review on HCV treatment in 
community settings. We included all types of quantitative and qualitative studies and 
considered all important outcomes of HCV treatment to produce a comprehensive review of 
the evidence on the provision of HCV treatment in different community settings. 
 
However, our systematic review has some limitations. A majority of included quantitative 
studies were descriptive studies without comparison groups. Different exclusion and 
inclusion criteria were used, medicines were prescribed and ways were applied to measure 
some outcomes such as treatment adherence and uptake across the different studies.  
 
Clinical effectiveness 
Rapid virological, early virological and end of treatment responses are comparable for 
community based and tertiary models. Based on the reviewed studies at least 62% and 75% 
of patients achieved RVR and EVR, respectively.
25, 40, 43, 50, 58
 In a meta-analysis, RVR of 
about 31% and EVR of about 68% were reported for patients who received Peg-IFN plus 
RBV.
66
 For interferon based treatment, because EVR and RVR are predictors of SVR, care 
providers would test clients at these intervals to monitor treatment effectiveness and decide 
whether to continue, change or terminate the treatment regimen.
67
 However, in DAA 
regimens, HCV RNA testing during treatment is not necessary, but is recommended in cases 
with concern about non-adherence to treatment and patients with decompensated liver 
disease.
2
 Included studies reported ERT of 48·7% in interferon plus RBV  based treatment
18
 
and 96% in interferon free regimen.
29
 In a systematic review of RCTs, ETR were 53% and 
67% in patients who received interferon plus RBV and Peg-IFN plus RBV, respectively.
68
 In 
another systematic review, ETR was reported as about 77% among patients who receive Peg-
IFN plus RBV.
66 
 
The incidence of serious side effects requiring treatment termination in community-based 
models is similar to or less than the tertiary based models and varied from 3·3% in interferon 
free treatment
47
 to 27·8% where patients received Peg-IFN plus RBV.
22
 In a systematic 
review of 18 RCTs, discontinuation of treatment because of severe side effects was reported 
in 17% and 21% of patients who received Peg-IFN plus RBV and interferon plus RBV, 
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respectively.
69
 A systematic review on 41 studies including RCTs and cohort studies reported 
a range from 2% to 16% of treatment discontinuation in patients who received Peg-IFN plus 
RBV and from 9% to 26% and 8% to 25% in patients who received telaprevir or boceprevir 
plus Peg-IFN plus RBV, respectively.
70 
 
The SVR from community-based models is compatible with or higher than SVR reported in 
systematic review on tertiary based treatment. Included studies reported SVR in a range from 
22·3%
22
 where patients were treated by PEG-IFN plus  RBV to 95·5%
34
 where the majority 
of patients received interferon free treatment. Only in six studies SVR rate was less than 
50%
18, 22, 31, 36-38
 where in two of them patients received interferon plus RBV.
18, 37
 In three 
systematic reviews, 32%, 33% and 38% of patients who received interferon plus RBV 
achieved SVR.
69, 71, 72
 In another systematic review on 18 RCTs, only 50% for patients who 
received Peg-IFN plus RBV achieved SVR.
69
 In a systematic review on studies among people 
who inject drug (PWID) in Europe median of SVR was 55% ranged from 19% to 88% for 
PEG-IFN plus  RBV regimen.
73
 In a systematic review SVR12 among treatment naïve HCV 
genotype 1 in all DAA regimens without Peg-IFN plus RBV ranged from 93% to 100% and 
in patients who received Peg-IFN plus RBV was 48%.
74
 Two systematic reviews on 
interferon free treatment reported SVR12 in a range from 80% to 96%.
75, 76 
 
Relapse rates in community based models are comparable with tertiary based models. Risk of 
relapse after SVR achievement is reported as a challenge to treatment scale-up. Based on the 
findings of this review, relapse rates in community settings ranged from 16·7% in a study on 
Peg-IFN plus RBV based treatment
28
 to 2·2 in a study where patients received DAA 
regimens.
34
 In a systematic review on RCTs 4·5% relapse was reported for interferon free 
therapy.
75
 Relapse is more highlighted in HIV infected patients due to their impaired immune 
system.
77
 Among included studies in this systematic review which reported relapse rate, in 
one study,
28
 HIV infection was not mentioned as an exclusion criteria and in another study
34
 
24% of the patients were HIV positive.  
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Acceptability 
There is insufficient knowledge about HCV treatment uptake in community settings. Globally 
HCV treatment uptake is about 1%.
3, 78
 Treatment uptake was measured in different ways in 
different studies due to varying inclusion and exclusion criteria. The conclusion of the 
reviewed studies is that treatment uptake was greater in community settings. The qualitative 
studies revealed that patients are more likely to initiate treatment in the community setting as 
they experience primary care providers as being friendly and understanding, and that 
community settings are perceived as familiar, safe, trusted and easy to access.
60-63
 It was also 
mentioned by some patients that they are not comfortable to receive HCV treatment at OST 
clinics.
60, 64
 In a systematic review it was demonstrated that co-location of HCV treatment 
with mental health and addiction services cannot significantly improve the treatment 
uptake.
79
 Treatment uptake between 0% and 60% (median 30%) was reported among PWID 
and between 24% and 76% (median 55%) among PWID plus additional criteria e.g. HCV 
genotype or drug use status.
80
 In a review of evidence it was reported that only about 30% to 
40% of evaluated patients in referral centres initiated the treatment.
81
  
 
Based on this review providing HCV care in community settings increased adherence to 
HCV treatment. The included studies used different measures to assess patients' adherence to 
treatment. Overall adherence to treatment in terms of attending expected visits and receiving 
prescribed medicines was more than reported figures from tertiary based treatment. In a 
systematic review on RCTs, 66% of patients remained in the trials for at least 80% of 
duration and received at least 80% of prescribed medicines.
68
 In another systematic review 
the adherence to treatment among patients who received treatment at tertiary centres was 
reported from 38% (taking at least 80% of Peg-IFN plus RBV) to 89% (taking at least 80% of 
RBV).
82
 Adherence to treatment is a strong predictor for SVR. SVR among patients who at 
least took 80% of the prescribed PEG-IFN and RBV for at least 80% of the recommended 
treatment course was higher than those who did not.
68, 83 
 
The completion rate in this review was better than reported in systematic review on tertiary 
based treatment and ranged from 33·4% in Peg-IFN plus RBV based treatment
22
 to 100%
34
 in 
interferon free regimen. In five studies the completion rate was less than 60%.
20, 22, 35, 36, 48
 
Included qualitative studies revealed that in community setting patients are more likely to 
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continue the treatment as they feel comfortable
60, 61, 64
 and experience positive psychological 
and behavioural changes.
59
  In a systematic review it was shown that co-location of HCV 
treatment with mental health and addiction services improved treatment completion rate.
79
 In 
a study on national cohort of HCV infected veterans in USA where patients received PEG-
IFN (26·9%) or interferon (73·1%) reported only 22·5% of veterans completed a 48 week 
course of treatment for HCV.
84 
 
Further research 
We could not find any studies of the cost-effectiveness of community-based models. It would 
be helpful to have a better understanding of the cost-effectiveness of these models for treating 
HCV. There is also a lack of knowledge regarding the effects of community-based models on 
re-infection rates. We only found one study from low and middle income countries. More 
research in these countries is urgently needed to support equitable HCV treatment access and 
global HCV elimination goals. Strategies such as international collaboration may be helpful 
for facilitating this research.
21
 The organisational and operational elements of successful 
community-based models, and barriers and enablers to obtaining HCV treatment in 
community settings, need to be understood, especially in the context of DAA regimens. 
 
The application of this review in the era of DAA regimens  
This review provides lessons for developing clinically effective and acceptable community-
based models for treating HCV, using efficacious DAAs in routine practice. In terms of 
clinical effectiveness, all community-based models included in this review provided supports 
for health care practitioners, such as specialist mentoring and training. These supports may 
have enabled practitioners to achieve clinical outcomes similar to or better than tertiary based 
models. Although the efficacy and safety of DAAs, compared with the interferon-based 
therapies, has removed major treatment-related barriers, primary health care practitioners 
require training and support to provide HCV care as part of routine practice, so that the 
opportunities to increase uptake in community settings can be maximised. 
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To reach the HCV elimination target for treatment uptake of 80% in 2030, the characteristics 
of HCV patients need to be understood to ensure the DAA regimens are easily accessible. 
Based on this review, community-based models implemented in various settings appeared to 
make treatment easy to access for different groups of patients. However, although we found 
that providing HCV treatment in community settings increased treatment uptake, there is still 
some uncertainty regarding the level of uptake achieved, and the contribution of service 
accessibility on the willingness of patients to initiate treatment. In the DAA era, various 
models are needed to facilitate access to treatment for different population groups. This is 
especially important in ‘hard to reach’ groups such as PWID. Further, data on the 
geographical distribution of HCV infection should be developed to plan for locally accessible 
services.  
 
Acceptability of treatment is another factor that needs to be considered. Apart from the 
efficacy of HCV therapies, many factors related to service provision, including the 
appropriateness of the clinic environment and support for patients, are likely to influence 
rates of uptake and cure. This review demonstrates that communication between care 
providers and patients in a safe and trusted environment are the key factors to making the 
HCV treatment service acceptable. In studies of both the interferon-based and DAA 
regimens, various initiatives were implemented to support patients during treatment to 
increase treatment adherence and completion rates. In routine practice, HCV care providers 
need to be trained and supported to understand HCV patients’ expectations. Also, patients’ 
characteristics need to be assessed and where needed psychological and social supports 
should be provided to improve patients’ engagement with the service. A model involving a 
‘one-stop shop’, wherein a multidisciplinary service was provided to respond holistically to 
patient’s health needs, was highlighted in this review as a factor that increased patient’s 
willingness to initiate treatment. The co-location or linking of HCV treatment with related 
services, such as harm reduction and drug and alcohol services, also should be considered.  
 
Only one study was from low- and middle-income countries. A likely issue in low and middle 
income countries relates to the limited available research. There may some types of 
community-based models implemented but they are not evaluated, reported or published. It is 
important to consider the health service infrastructure and availability of DAAs in these 
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countries. In many low and middle-income courtiers there is more of a focus on increasing 
the HCV diagnosis rate and addressing medicine affordability.
85
 Consequently, the 
development of models for provision of community-based treatment may be less of a priority. 
It is important that both HCV testing and DAA treatment are affordable and available. In low 
and middle income countries opportunities for implementing various community-based 
models need to be assessed and appropriate approach taken to provide accessible, affordable, 
effective and acceptable HCV treatment.  
Conclusion 
The community-based models for treating hepatitis C viral infection that were included in 
this systematic review have shown impressive outcomes. Although a majority of the included 
studies examined the provision of interferon-based therapies, which were more complicated 
than the recent DAA therapies, the outcomes reported by the listed studies are similar to or 
better than outcomes reported in published systematic reviews on studies from tertiary 
settings. Treatment clearly needs to be provided in community settings so that HCV cures 
rates can be increased and global elimination goals met. Support for health care providers and 
patients is critical and should be carefully considered in developing community-based 
models. Overall, this mixed methods systematic review demonstrates that the provision of 
hepatitis C viral treatment in community settings is clinically effective, can increase 
treatment uptake, adherence and completion rates, and is favourably received by patients. 
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Figure 1: PRISMA flow diagram of search and study selection process 
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Table 1: Characteristics of included quantitative studies 
Study Study 
design 
Date of data 
collection 
Country Sample size Setting  Medicine Outcomes HIV and 
HBV Co-
infections  
Alavi et al39 Cross 
sectional 
February 2009-
December 2012 
 
A
u
st
ra
li
a 
387  Opioid 
substitution 
treatment clinics, 
community health 
clinics, aboriginal 
community 
controlled health 
organisation 
PEG-IFN α 
2a/2b + RBV 
Uptake: 22%  Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Arora  et al55 Cohort September 2004- 
December 2009 
U
S
A
 
407 (261 in 
ECHO vs. 
146 in 
University of 
New Mexico 
(UNM) 
clinics) 
Primary care 
clinics vs. UNM 
clinic-based 
PEG-IFN + 
RBV 
UNM vs. Echo 
SVR: 57·5% vs. 58·2% (non-
significant). Serious adverse 
events requiring termination 
of treatment 8·9% vs. 4·2% 
(P = 0·05). 
excluded 
Baker et al40 Cross 
sectional 
November 2010-
June 2012, follow 
up March 2013 
A
u
st
ra
li
a 
41  Primary care 
clinics  
PEG-IFN α-
2a/2b+ RBV 
Completion: 83%, RVR: 
65·9%, EVR: 75·6%, ETR: 
78%, SVR: 71%, 
hospitalization: 12% 
HIV+: 4·9% 
Beste  et al56 Cohort  April 2011- June 
2015 
U
S
A
 
6947 
initiated 
treatment 
(total 
regimens= 
7785) 
Primary care 
clinics  
Unclear  non-ECHO vs. VA-ECHO 
SVR: 53·9% vs. 58·2% (p= 
0·32) 
 
HIV+: 1·8% 
of exposed, 
2·3% of 
unexposed 
Bruce  et al58 randomized 
controlled 
trials 
2007-2010 
U
S
A
 
Methadone 
maintenance 
program (n= 
12) vs. 
university 
liver 
specialty 
clinic (n= 9) 
Community-based 
methadone 
maintenance 
program vs. 
university based 
liver speciality 
clinic   
 
PEG-IFN α-
2a + RBV 
Methadone maintenance 
program vs. university liver 
specialty clinic  
EVR: 83·3% vs, 75%, SVR: 
50% vs, 25%.  
HIV+: 25% 
Methadone 
maintenanc
e program 
vs. 33% 
university 
liver 
specialty 
clinic 
Burunner et 
al41 
Cross 
sectional 
2002-2010 
S
w
it
ze
rl
an
d
 
66 Opioid 
maintenance 
treatment  
PEG-IFN α 
2a/2b + RBV 
Completion: 68·2%, SVR: 
62% 
HIV+: 11% 
Calvert et al 
20 
Cross 
sectional 
January 2000- 
December 2002 
U
S
A
 
40 eligible 
for treatment 
Health 
maintenance 
organization 
health care 
management 
company  
PEG-IFN + 
RBV 
Completion: 52·6%, SVR: 
27·5% 
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Capileno et 
al21 
Cross 
sectional 
February to 
December 2015 
P
ak
is
ta
n
 
169 initiated 
treatment 
Community-based 
primary care clinic 
Sofosbuvir + 
Ribavirin and 
for G1 + Peg-
IFN 
SVR 12: 83·4%, 
Relapse: 3% 
Was not an 
exclusion 
criterion 
but data 
were not 
reported 
A
cc
ep
te
d 
A
rt
ic
le
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Charlebois et 
al42 
Cross 
sectional 
March 2007- July 
2010 
C
an
ad
a 
110 CHCV+, 
24 initiated 
treatment 
Community health 
centres 
PEG-IFN + 
RBV 
(Before vs. After new model) 
Assessed by specialist: 18·6% 
vs. 58·9%, adherence (only 
after): 87·5%, 3 patients had 
missed PEG-IFN, SVR (only 
after): 70·8% 
HIV+: 
6·1%, 
HBV+: 
0·9% 
Grebely et 
al23 
Cross 
sectional 
January 2002- 
march 2005 
C
an
ad
a 
40 initiated Community health 
centre 
PEG-IFN α 
2a/2b + RBV 
Completion: 62%, SVR: 55%, 
ETR: 70%, Treatment 
limiting adverse events: 
12·5% 
HIV+: 7·5% 
Grebely et 
al22 
Cross 
sectional 
March 2005- over 
a period of 80 
weeks 
C
an
ad
a 
80 referred, 
18 initiated 
treatment at 
the study site 
Community health 
centre 
PEG-IFN α 
2a/2b + RBV  
Uptake: 26·2%, adherence: 
57·8%, completion: 33·4%, 
ETR: 67%, treatment limiting 
adverse events: 27·8%, SVR: 
22·3% 
HIV+: 22% 
Grebely et 
al44 
Cross 
sectional 
March 2005- 
March 2008 
C
an
ad
a 
109 assessed, 
57 initiated 
treatment, 
outcome data 
of 19 patients  
Community health 
centre 
PEG-IFN α 
2a/2b + RBV  
Uptake: 60%, SVR: 63%  HIV+: 11% 
Grebely et al 
43 
Cross 
sectional 
February 2009-
December 2012, 
follow-up: June 
2014 
 
A
u
st
ra
li
a 
101 Opioid 
substitution 
treatment clinics, 
community health 
clinics, aboriginal 
community 
controlled health 
organisation 
PEG-IFN α 2a 
or PEG-IFN α 
2b + RBV  
Adherence  
(80% of scheduled doses and 
80% of scheduled treatment 
period): 86%, RVR: 62%, 
EVR: 86%, ETR: 76%, SVR: 
74%  
HBV+:3%, 
HIV+ 
persons 
were not 
excluded 
but data 
were not 
reported 
Hampton et 
al17 
Cross 
sectional 
Pilot 2008-2009 
and main study 
2009-2011 
U
K
 
Pilot =10, 
Main study = 
33 
Community drug 
and alcohol 
service 
PEG-IFN + 
RBV 
Completion: 95·3%, SVR: 
72·1%, relapse: 14%  
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Hill et al24 Cross 
sectional 
September 2001- 
December 2005 
C
an
ad
a 
471 eligible, 
363 initiated 
treatment 
Rural and small 
town health 
centres 
IFN + RBV 
Or PEG-IFN 
+ RBV 
Uptake: 77%, SVR: 61%  Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Ho et al25 Cross 
sectional 
Not mentioned 
U
S
A
 
30 initiated 
treatment 
Community-based 
clinic  
PEG-IFN α 2 
+ RBV 
Adherence to medical plan 
(attending > 80% of 
recommended visits): 77%, 
Adherence to medicine 
(taking ≥ 80% of prescribed 
doses): 80%, Completion: 
80%, intolerable adverse 
events: 6·7%, EVR (only for 
G1): 90%, ETR: 76·7%, 
SVR: 63·3%  
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
A
cc
ep
te
d 
A
rt
ic
le
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Jack et al27 Cross 
sectional 
February 2005- 
January 2008 
U
K
 
43 eligible 
for treatment, 
30 initiated 
treatment 
General 
practitioner clinics  
PEG-IFN α 
2a/2b + RBV 
Uptake: 69·7%, Completion: 
81%, SVR: 81% 
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Jack et al26 Cross 
sectional 
February 2004- 
January 2012 
U
K
 
88 referred 
for treatment, 
81 initiated 
(87 episode)  
 
Home care PEG-IFN α 
2a/PEG-IFN α 
2a/2b + RBV 
Uptake: 92%, Completion: 
92·5%, ETR: 11·3%, SVR: 
45% 
Among 88: 
HIV+: 5, 
HBV 
infected 
patients 
were 
excluded 
from 
analysis for 
this paper 
Jeffrey et al45 Cross 
sectional 
October 2002- 
March 2005 
A
u
st
ra
li
a 
50 initiated 
treatment 
Community clinic IFN α 2b + 
RBV Or PEG-
IFN α 2b + 
RBV 
ETR: 66%, SVR: 62% HIV+ 
excluded 
John-
Baptiste et 
al46 
Cross 
sectional 
November 2002- 
January 2006 
C
an
ad
a 
109 Addiction 
treatment centres 
PEG-IFN α 
2a/2b + RBV 
Completion: 65%, SVR: 56%  Excluded 
Kattakuzhy  
et al47 
Cross 
sectional 
20 Jan 2015-24 
Nov 2015 
U
S
A
 
600 Community base 
clinics   
ledipasvir 
(LDV) and 
sofosbuvir 
(SOF) 
Adherence to all treatment 
visits: 62·2%, adherence to 
prescriptions: 86·6%, SVR: 
86, Relapse: 5·8%, Treatment 
limiting adverse events: 
3·33%  
HIV: 23%,  
HBV 
included 
but data 
was not 
reported 
Keats  et al48 Cross 
sectional 
February 2009- 
June 2014 
A
u
st
ra
li
a 
242 attended 
an 
assessment 
by HCV 
clinician, 20 
initiated 
treatment 
Opioid 
substitution 
treatment clinic  
PEG-IFN + 
RBV  
Uptake: 8·3%, Completion: 
55%, SVR: 75%, 
Treatment limiting adverse 
events: 20%  
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Lewis  et al28 randomized 
controlled 
trials (both 
community 
based then 
we 
considered 
it as a 
cross-
sectional) 
September 2011- 
July 2012 
U
K
 
76 standard 
care 
(specialist) 
(control) and 
62 nurse-led  
Specialist 
addiction units at 
community and 
community 
outreach clinics 
PEG-IFN α 2a 
+ RBV 
(specialist and nurse-led) 
Uptake: 9% and 10% (P = 
0·53), Adherence (receiving 
≥80% of interferon and 
ribavirin doses for ≥80% of 
the expected duration of 
therapy): 83% and 83%, ETR: 
83% and 83%, SVR: 50% and 
66·7% (no difference), 
relapse: 0 and 16·7 
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
A
cc
ep
te
d 
A
rt
ic
le
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Lindenburg 
et al49 
Cross 
sectional 
January 2005-
September 2010 
N
et
h
er
la
n
d
 
 
58 initiated 
treatment 
Community health 
centres  
PEG-IFN α 
2a/2b + RBV 
Uptake: 76%, ETR: 82·8%, 
Relapse: 20·8%, SVR: 65%, 
Adherence to medical plane: 
95% attended the scheduled 
plan 
HIV+ 
excluded  
Litwin  et 
al50 
Cross 
sectional 
January 2011- 
April 2013 
U
S
A
 
50 Methadone 
maintenance 
treatment clinics 
Telaprevir or 
boceprevir + 
PEG-IFN α 2a 
+ RBV 
RVR: 68%, EVR: 60%, ETR: 
70%, SVR: 62%, Adherence 
(≥ 90) to ribavirin: 74%, to 
telaprevire/ bocoprevir: 64%  
Exclude  
Mason et al51 Cross 
sectional 
January  2011-
2012 
C
an
ad
a 
78 patients, 
15 initiated 
treatment 
Community-based 
primary care 
centres 
Not reported  (Baseline vs. 1 year after new 
model) HCV specialist 
access: 15% vs. 54% (P= 
0·002), Uptake: 4% vs. 19%, 
completion: 60%, SVR: 40% 
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Mason  et 
al29 
Cross 
sectional 
2015 
C
an
ad
a 
74 initiated, 
69 due to 
SVR at the 
study time 
Community-based 
primary care 
centres 
 
DAAs or 
sofosbuvir 
and ribavirin 
Completion:97%, ETR: 96%, 
SVR: 87%, 41% of 
participants had at least one 
missed dose 
Not 
excluded  
but data 
was not 
reported 
Milne  et al30 Cross 
sectional 
2004-2014 
C
an
ad
a 
131 initiated 
treatment 
Community health 
centre 
PEG-IFN α 2a 
+ RBV 
SVR: 77% 
 
HIV+ 
between 
2012-2014: 
23·9%  
Morris  et 
al52 
Cross 
sectional 
March 2016-
February 2017 
A
u
st
ra
li
a 
127 Community based 
alcohol and drug 
health services 
DAAs with 
and without 
ribavirin 
Completion: 96·1%, SVR: 
80·3%, ETR: 89%, 
Adherence (defined as taking 
at least 90% of doses): 97% 
Not 
excluded  
but data 
was  not 
reported 
Moussalli et 
al31 
Cross 
sectional 
January 2002- 
December 2004 
F
ra
n
ce
 
337, 85 
initiated 
treatment 
Addiction centre  
vs. hospital 
Not 
mentioned  
Uptake: 2% in hospital, 38% 
in addiction centre (P < 
0·001), SVR: 44% 
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Nazareth  et 
al32 
Cross 
sectional 
August 2006- 
2010 
A
u
st
ra
li
a 
Telehealth 
(TH) 53 
referred 50 
initiated 
treatment (3 
ineligibles), 
face-to-face 
(FTF) 559 
Telehealth clinics 
vs. face-to-face 
hospital clinic  
PEG-IFN + 
RBV 
TH: Completion: 70%, 
Adverse effects: 10%, SVR: 
72%, Relapse: 4% 
FTF: SVR: 55·6%  
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Newman  et 
al33 
Cross 
sectional 
June 2006-
Decemper 2008 
C
an
ad
a 
 
  
34, 14 
initiated 
treatment 
Community health 
centre providing 
addiction services 
PEG-IFN α 2a 
or PEG-IFN α 
2a + RBV 
Uptake: 41%, Completion: 
71·4%, Adherence (≥ 80% 
prescribed dose): 100%, ETR: 
78·6%, SVR: 57%  
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
A
cc
ep
te
d 
A
rt
ic
le
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Norton  et 
al34 
Cross-
sectional 
Jan 2015- Aug 
2015 
U
S
A
 
       
89 initiated 
 
Community-based 
primary care clinic  
DAAs or 
Sofosbuvir 
and ribavirin 
or Sofosbuvir, 
peglyated-
interferon and 
ribavirin,  
Completion: 100%, Relapse: 
2·2%, SVR: 95·5% 
HIV+: 24% 
Read  et al53 Cross- 
sectional 
2015-2016 
A
u
st
ra
li
a 
72 initiated 
treatment 
Community-based 
primary health 
care facility 
DAAs ± 
ribavirin  
Completion: 96%, SVR: 82% HIV+: 11%, 
HBV+: 0  
Rossaro et 
al57 
Cohort 2006-2010 
(months are not 
mentioned) 
U
S
A
 
40= 
Telemedicine 
(TM), 40= 
hepatology 
clinic (HC) 
Telemedicine vs. 
hepatology clinic 
PEG-IFN + 
RBV 
(HC vs. TM) 
Completion: 53% vs. 78% 
(P= 0·03), SVR: 43% vs. 55% 
(P= 0·36)  
Excluded 
Seidenberg  
et al54 
Cross 
sectional 
January 2002- 
May 2008 
S
w
it
ze
rl
an
d
 
85, 35 
initiated 
treatment 
Office based 
opioid 
maintenance 
treatment 
PEG-IFN α 2a 
+ RBV 
Uptake: 41·2%, ETR: 80%, 
SVR: 71·4%, relapse: 8·6%  
HIV+ :  
14·7% in 1 
patient data 
was missed 
Stringari-
Murray et 
al35 
Cross 
sectional 
November 1998-
December 2002 
U
S
A
 
248, 26 
initiated 
treatment 
HIV/AIDS 
Specialty clinic in 
the community 
IFN+ RBV Uptake: 10·5%, Completion: 
47·8%, Treatment stopping 
adverse events: 23·1% 
Not 
mentioned 
as an 
exclusion 
criterion 
but data 
was not 
reported 
Sylvestre  et 
al37 
Cross 
sectional 
Not reported 
U
S
A
 
71 Community-based 
clinic  
IFN α 2a + 
RBV 
Adherence (took >80% of 
prescribed interferon and 
>80% of prescribed ribavirin 
for at least 80% of the 
recommended treatment 
course): 68%, completion: 
76%, SVR: 29·6%, 
Intolerable side effects: 
11·3%   
HIV+:1·4%  
Sylvestre  et 
al18 
Cross 
sectional 
Not reported 
U
S
A
 
76 Community-based 
clinics  
IFN α 2a + 
RBV 
Adherence (>80% of 
prescribed interferon and 
>80% of prescribed ribavirin 
for at least 80% of the 
recommended treatment 
course): 68·4%, Completion: 
76·3%, ETR: 48·7%, SVR: 
27·6%, Intolerable systemic 
side effect: 10·5%  
HIV+: 1·3% 
Sylvestre36 Cross 
sectional 
Not reported 
U
S
A
 
28 Community-based 
clinics 
PEG-IFN α 2a 
+ RBV 
(One patient ongoing 
treatment) 
Completion: 92·5%, ETR: 
78%, SVR: 44·4% 
 
Not 
mentioned 
as a 
exclusion 
criteria but 
data was 
not reported 
A
cc
ep
te
d 
A
rt
ic
le
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Wade  et al19 Cross 
sectional 
April 2011- 
August 2014 
A
u
st
ra
li
a 
279, 55 
initiated 
treatment  
Outreach clinics  PEG-IFN + 
RVB, or 
PEG-IFN 
+RBV+ 
DAAs 
Uptake: 20%, SVR: 61% HIV+: 
1·8%, 
HBV+: 
5·5% 
Wilkinson  et 
al38 
Cross 
sectional 
2005-2007 
U
K
 
441, 63 
initiated 
treatment 
Outreach clinic in 
the central 
specialist 
addiction unite 
PEG-IFN α 2a Uptake: 14·3%, completion: 
92·1%, adherence (taking 
>80% of the prescribed drugs 
for 80% of the time): 81%, 
SVR: 43% 
HIV+: 0, 
HBV+: 0 
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Table 2: Characteristics of included qualitative studies 
Study 
D
a
te
 o
f 
d
a
ta
 
co
ll
ec
ti
o
n
  
Methodology, method, data 
analysis method 
Participant Setting and 
geographical 
location 
Medicine 
Batchelder  et al59 
Ju
n
e 
2
0
1
1
 t
o
 
M
ar
ch
 2
0
1
3
 
Not mentioned, 
Interview, thematic analysis 
31, of whom 26 completed 
treatment, 5 discontinued 
Methadone 
maintenance clinic, 
USA 
Only mentioned 
interferon-based 
treatment 
Harris  et al60 
Ju
n
e 
2
0
1
1
- 
Ja
n
u
ar
y
 2
0
1
2
 Qualitative case study, in-depth 
interview facilitated by a topic 
guide, thematic analysis  
35 PWID of whom 12 completed 
treatment (9 successful), 6 in 
midst of treatment, 13 waiting for 
or contemplating treatment, and 
for 4 treatment were interrupted 
Drug and alcohol 
service, 
UK 
Not reported 
Hopwood and 
Treloar61 
S
ep
te
m
b
er
 
2
0
1
0
 t
o
 
N
o
v
em
b
er
 
2
0
1
1
 
Qualitative  program evaluation, 
two brief  structured telephone 
interview 9 open-ended 
questions, Descriptive content 
analysis 
8 male patients with G2 and G3 
completed treatment 
General practice, 
Australia 
Not reported 
Norman et al62 
S
ep
te
m
b
er
 2
0
0
6
 Qualitative program evaluation, 
Semi-structured interview 
(group interview), thematic 
analysis 
9 clients of healthy liver clinic. 
Five undergoing HCV treatment 
and four who were eligible and 
waiting to commence HCV 
treatment  
Community drug 
and alcohol clinic, 
Australia 
Peg-IFN and RBV 
Rance and Treloar63 
B
et
w
ee
n
 2
0
0
9
 
an
d
 2
0
1
2
 
Qualitative program evaluation, 
semi-structured interview, 
thematic analysis 
57 clients (17 no assessment, 21 
initial assessment, 19 awaiting or 
initiated treatment)  
Opioid substitution 
therapy clinics, 
Australia 
Not reported but 
based on ETHOS 
model Peg-IFN α 
2a,/PEG-IFN α 2b + 
RBV  
Treloar et al64 
B
et
w
ee
n
 2
0
0
9
 a
n
d
 2
0
1
2
 
Program evaluation, semi-
structured interview,  
thematic analysis 
57 clients (17 no assessment, 21 
initial assessment, 19 awaiting or 
initiated treatment)  
Opioid substitution 
therapy clinics, 
Australia 
Not reported but 
based on ETHOS 
model Peg-IFN α 
2a,/PEG-IFN α 2b + 
RBV 
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Table 3: Outcomes of the different community-based models for treating HCV 
Type of 
model 
Locations  Clinical effectiveness Acceptability 
RVR and 
EVR 
ETR Serious 
side 
effects 
SVR Relapse 
rate 
Treatme
nt 
uptake 
Adherence 
to 
treatment 
Completi
on 
Telehealth  USA
55-57 
Australia32 
- - 4·2%55 
and 
10%32  
 
Ranged 
from 55%  
to 72% 
 
4%32 - - 78%57 
and 
70%32 
 
 
Integration 
of HCV and 
addiction 
services 
Australia19, 39, 43, 45, 
48, 52  
Canada22, 23, 30, 33, 
44, 46  
USA18, 36, 37, 50, 58 
UK17, 27, 28, 38 
Switzerland41, 54 
France31 
Nederland49 
RVR: 
68%50 and 
62% 43 
EVR: 
86%49 and 
83·3%64 
Ranged 
from 
48·7% 
to 89%  
Ranged 
from 
11% to 
27·8% 
Ranged 
from 
22·3%  to  
80·3% 
8·6%,60 
14%23 
and 
16·7%28 
Ranged 
from 
8·3%  to 
69·7% 
Ranged 
from 
68·4% to 
100% of 
patients 
who 
received 
≥80% of 
prescribed 
doses. 
Ranged 
from 
33·4% to 
96·1%  
HIV/HCV 
integration 
model 
 
USA35 - - 23·1%35 - - 10·5%35 - 47·8%35 
Integration 
of HCV and 
primary care 
models 
 
Canada24, 29, 42, 51 
USA25, 34, 47 
Australia40, 53 
Pakistan21 
RVR: 
65·9%40  
EVR: 75·6, 
40 90%25  
 
76·725  
 and 
96%29  
3·3%47 
and 
6·7%30  
 
Ranged 
from 40%  
to 95·5%  
 
2·2%,34 
  3%21 
 and 
5·8%47 
Ranged 
from 
19% to 
77%  
≥80% of 
patients 
received 
≥80% of 
prescribed 
doses. 
Ranged 
from 
60%  to 
100%  
Home care 
and health 
care 
management 
companies  
UK26 
USA20 
 
- 11·326  - 27·5%20 
and 45%26  
 
- 92%26 - 92·5%26  
and 
52·6%20  
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Table 4: Results of meta-synthesis of qualitative research findings under synthesised findings 2 
Findings Supporting quotes Categories  Synthesised 
finding 
Being listened to (U) “The doctor that’s runnin’ the show . . . he treats me like a 
friend,. . .. . . ’Cause some people need to be listened to ... and 
he just listened” 63 p.456. 
Trusted and 
supportive 
care providers 
Community 
based model 
of care for 
HCV 
treatment is 
an easy to 
access care 
in a trusted, 
safe and 
supportive 
environment 
which can 
engage 
patients to 
treatment 
and improve 
their quality 
of life. 
 
 
Access to emotional support, and 
high levels of trust in GPs (U) 
“… the reason I took it up was … purely because my GP sort 
of assured me that, “If anything goes wrong, we’re there for 
you all the time.” So … I felt more comfortable” 61 p.901. 
Familiarity with individual service 
providers aids engagement, (U) 
“I wouldn’t have gone to that [service] if it hadn’t been for 
her [BBV nurse]” 60 p.22. 
Experience of being recognized 
beyond the immediate and 
instrumental needs of their daily dose 
(U) 
“It was nice to know that somebody actually looked out for 
Tracy, not just ‘Methadone Tracy’ . . . I had other issues. And 
it [HCV] was something I didn’t wanna address. And she [the 
ETHOS clinician] helped me address it” 63 p.456. 
The quality of the therapeutic 
interaction was equally noteworthy, 
if somewhat more clinically 
orientated (E)  
“… she [the ETHOS nurse] helps me, tells me nothing but the 
truth about it [HCV] and I do everything she says . .. . 
Explained it to me properly why I should take it [HCV 
medication], … Why I should keep taking it. Nobody in the 
gaol told me that” 63 p.456. 
convenience, safety and personal 
care provided by their GPs and 
practice nurses (U) 
“… [My GP] has people to do the blood tests. … . And, since 
you’ve known them for a while, you do feel comfortable” 61 
p.902. 
Respectful treatment (U) “Whereas you think you’re more likely to be treated 
respectfully in a context like [the OST clinic] . . . ‘cause we 
see ‘em each day and they get to know you. . . . yeah, they 
treat you normal.” 64 p.531. 
Welcoming and non-judgmental 
attitude of HCV staff (U) 
“… You can talk to ‘em a lot better. They don’t look down 
on you. … They explain every- thing...” 64 p.531. 
Feeling guided and supported 
rather than rushed or pushed 
into treatment (U) 
“. . .they don’t push it on people. … So it’s the person’s 
choice, … And if they don’t want to be involved with it, 
they don’t have to” 64 p.531. 
develop long-standing relationships 
with particular ‘keyworkers’ (U) 
“was like a big brother.we were close” 60 p.22. 
The co-location of HCV and 
OST services raised concerns 
around conﬁdentiality and the 
risk of losing access to OST (E) 
“… people who “aren’t connected to the OST clinic” 
should run HCV treatment in OST, fearing that “personal 
grudges” of OST staff could result in clients not receiving 
their “dose”” 64 p.532. 
Co-location of HCV care providers 
with OST prescribers could pose a 
symbolic barrier to trust for service 
users (E)  
It’s just sit there and keep your head down and shut up 
because they’re writing your scripts. … the person who 
writes the script, they hold the power; you’re not going 
do anything to piss them off. 60 p.24. 
Feeling safe place (U)  “We come here [OST] anyway. We feel safe coming here 
…” 64 p.531. 
Safe and 
trusted setting 
 Feeling at ease and comfortable 
at the clinic (E)  
"I don't worry when I'm here"62 p.3. 
Familiarity of the setting (U)  Because you’re more familiar with the place … So you’re 
more likely to talk about it. 60 p.22. 
Inevitable, if  unintended, 
disclosure of  HCV status 
because of physical layout of 
“.. the only thing that I could think of is their privacy. Like 
they’d be too ashamed. . . . ‘Cause it’s not a very big 
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OST clinic (U) clinic...” p.532.64 
Integrated HCV treatment 
within a specialist alcohol and 
drug treatment centre was 
viewed as easy to access ( E )  
"making it easier" p.3. 62 Easy to 
access care 
The continual reminders about 
HCV in collocated services (U) 
“… when you come to the methadone service it’s bang in 
your face. … . Do it while you’re here” p.531.64 
Immediacy of access to care 
facilitate initiation the treatment 
(U) 
“. . . I wouldn’t have been able to do this if it wasn’t 
accessible through this clinic here and now. …” p.531.64 
Colocation facilitate continuing the 
treatment process (U) 
“. . . they’ve only just gotta walk upstairs and, or ask 
somebody in the clinic, ... I think havin’ all places in the 
one place make it a lot easier.” p.530.64  
Having multiple needs met at the 
one place ( U )  
"...my needs are met in a whole lot of different ways, from 
personal to support, to my addiction to ramifications from 
the addiction …" p.3.62  
Integrated model reduce travel 
costs (U) 
“Well obvious reasons: transport. … it’s public transport 
and going to the one venue for all your appointments is 
excellent. …” p.530.64  
Valuing or caring more after 
undergoing HCV treatment (U) 
“At ﬁrst I didn’t want to take care of myself. … . Today, I 
care how I look, how I dress, what people think of me, 
how they see the way I’ve changed,” p.68.59  
Psychological 
changes as a 
result of 
undertaking 
HCV 
treatment 
Change in ability to regulate 
emotions and be present for 
themselves (U) 
“Before I used to just get pissed off and give up. I haven’t 
given up on myself since [treatment],” p.68.59  
A new sense of hope after learning 
HCV viral load was undetectable 
(U) 
“I’m feeling good because now I got hope for [a] long life, 
I’m feeling good because I am undetectable. … .” p.68.59  
Recovery from internalized 
stigma and shame (U) 
“Everything I did during my addiction—I am not ashamed 
of it because I’m doing something to change,” 59 p.68. 
Change in HCV disclosure (U) “I’m on Hep C medication and …. I changed completely 
and I was okay with telling anybody who wanted to 
hear about the medication so they could get motivated,” 
p.68.59  
Behavioural 
changes as a 
result of 
undertaking 
HCV 
treatment Reductions in substance use 
behaviours. (U) 
“… I stopped drug use. I stopped everything because I 
said if I beat the Hep C, I could beat that too…,” p.68.59  
Sobriety and progression toward 
stable housing (U) 
“I noticed that I wanted to be sober. That getting high 
was no more fun—a waste of time, waste of money. …. 
right now we are in transition for housing, …,” p.69.59  
Transitioning into a healthier 
lifestyle (U) 
“… I take care of myself, from my weight to my diet-
everything. I’m real conscious of that,” p.69.59  
Increased sense of responsibility 
in their lives (U) 
“… when I started [HCV treatment], I guess I started 
being responsible. … making responsible decisions about 
my life. …” p.69.59  
HCV treatment and broader life 
transformation (U) 
“… saving my life,. . . So, coming into the hepatitis 
treatment really was a big turnaround,” p.69.59  
Desire to help others with HCV 
(U) 
“After the treatment, … What can I do to wake them up 
and let them know … ,” p.69.59  
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